Jazz Pharmaceuticals

Jazz Pharmaceuticals Forges Strategic Oncology Alliance with AbCellera for Next-Generation Multispecific Antibodies

Jazz Pharmaceuticals has partnered with AbCellera in a significant collaboration to develop next-generation T-cell engaging multispecific antibodies for GI cancer and solid tumors. This deal, valued at up to $792 million per program in milestones, plus royalties, underscores Jazz's strategic push into innovative oncology treatments. For decision-makers, this signals intensified competition in oncology and highlights the increasing reliance on specialized discovery platforms for pipeline diversification and future market positioning.